Sign in
Taking peopleNo phase

How the timing of clot-removing treatment affects people with sudden pulmonary embolism

Looks at when clot-opening treatment is given in adults with acute pulmonary embolism.

Key facts

Who runs it
Azienda ULSS 8 Berica
Where
Italy7 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Optimal Time for Reperfusion in Acute Pulmonary Embolism
Status
Recruiting
People taking part
500 people, planned
Started
25 Nov 2025
Planned end
30 Oct 2026
Type of study
Observational
Record updated
3 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a sudden blood clot in the lungs (acute pulmonary embolism) of high or intermediate-high risk. It is an observational study of how the timing of clot-removing treatment affects outcomes.

Age
18 years and older
Sex
All sexes can join.
Disease stage
High-risk or intermediate-high-risk pulmonary embolism, classified by the 2019 European Society of Cardiology guidelines. The diagnosis must be confirmed by CTPA (a CT scan of the lung arteries), pulmonary angiography, or echocardiography (heart ultrasound) showing a clot in the heart or main lung artery.

Main reasons for not taking part

  • Younger than 18 years
  • A high-risk or intermediate-high-risk pulmonary embolism was ruled out
  • Unable to give informed consent

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery)
  • Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines
  • Provision of informed consent for the processing of personal data

Who cannot take part

  • Age < 18 years
  • Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded
  • Inability to provide informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.

The group in the trial

  • Patients with intermediate-high or high-risk pulmonary embolism

    Patients with intermediate-high or high-risk pulmonary embolism stratified according to the ESC 2019 guidelines

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Optimal Time for Reperfusion in Acute Pulmonary Embolism
Plain-language title
How the timing of clot-removing treatment affects people with sudden pulmonary embolismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
3 March 2026